Ionizable Lipid Nanoparticles for Prolonged DNA Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering DNA molecules, such as viral vectors and non-viral plasmid-based vectors, face challenges including immunogenic responses, limited DNA capacity, high production costs, and inefficient long-term expression in vivo.
Innovation Solution
The use of ionizable lipid-based lipid nanoparticles (LNPs) to deliver DNA sequences, including circular or linear DNA vectors, which enhance cellular uptake, intracellular transport, and endosomal escape, while reducing immunogenicity and enabling prolonged tissue-specific protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for DNA delivery, then cellular uptake and initial expression are improved, but host immunogenic responses increase and production costs rise
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier to deliver DNA into cells. The LNP composition includes ionizable lipids, phospholipids, cholesterol, and PEG-lipids that work together to protect DNA, facilitate cellular uptake, and enable endosomal escape without triggering strong immune responses, thus resolving the contradiction between effective delivery and immunogenicity
Solution Approach 2:
The patent modifies the chemical parameters of the delivery system by using ionizable lipids with specific pKa values and controlled oxidation states. These parameter changes allow the LNP to remain stable in circulation but become active and release DNA at the target site, improving delivery efficiency while maintaining low immunogenicity
2Object-affected harmful factors
If non-viral plasmid-based vectors are used for DNA delivery, then safety is improved by reducing immunogenicity, but cellular uptake and long-term in vivo expression become less effective
Solution Approach 1:
The patent creates a composite delivery system combining ionizable lipids, phospholipids, cholesterol, and PEG-lipids in specific ratios. This composite LNP structure provides both the safety of non-viral delivery and enhanced cellular uptake and long-term expression through the synergistic effects of different lipid components
Solution Approach 2:
The ionizable lipids in the LNP exhibit dynamic properties that change with pH. They remain neutral in circulation for stability and safety, but become positively charged in the acidic endosomal environment to facilitate membrane disruption and DNA release, thereby enabling long-term expression without high immunogenicity
3Productivity
If viral vectors are used for DNA delivery, then gene transfer efficiency is improved, but the amount of DNA that can be carried is limited and production becomes expensive and labor intensive
Solution Approach 1:
The patent separates the delivery function from the genetic cargo by using a simple LNP composition that can accommodate large amounts of DNA. The LNP acts as a modular delivery vehicle that can be produced through straightforward mixing of lipid components, avoiding the complex viral vector production processes while maintaining high gene transfer efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves prolonged expression of desired polypeptides in target tissues, reducing immune activation and maintaining protein levels for several months, thus overcoming the limitations of existing DNA delivery methods.
Implementation Method 1
ionizable cationic lipid...improved properties when combined with a DNA sequence...improvements in cellular uptake
Implementation Method 2
lipid nanoparticle (LNP) delivery system...ionizable lipid-based LNPs...improved properties when combined with a DNA sequence
Implementation Method 3
ionizable cationic lipid...endosomal release or endosomal escape
Data Source
AI summary
The compositions and methods described herein relate to lipid nanoparticle encapsulation of circular or linear DNA sequences, including DNA vectors, for delivery into a subject such that prolonged expression in vivo occurs. Lipid nanoparticles containing DNA can be administered to a subject to express therapeutic polypeptides.